Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fortress Biotech (FBIO) Restructuring Costs (2016 - 2018)

Historic Restructuring Costs for Fortress Biotech (FBIO) over the last 3 years, with Q3 2018 value amounting to $1.7 million.

  • Fortress Biotech's Restructuring Costs fell 5218.84% to $1.7 million in Q3 2018 from the same period last year, while for Sep 2018 it was $7.3 million, marking a year-over-year decrease of 390.56%. This contributed to the annual value of $8.8 million for FY2017, which is 269619.05% up from last year.
  • Latest data reveals that Fortress Biotech reported Restructuring Costs of $1.7 million as of Q3 2018, which was down 5218.84% from $2.3 million recorded in Q2 2018.
  • In the past 5 years, Fortress Biotech's Restructuring Costs ranged from a high of $3.6 million in Q3 2017 and a low of $315000.0 during Q4 2016
  • In the last 3 years, Fortress Biotech's Restructuring Costs had a median value of $1.8 million in 2018 and averaged $1.9 million.
  • Per our database at Business Quant, Fortress Biotech's Restructuring Costs soared by 37396.83% in 2017 and then crashed by 5218.84% in 2018.
  • Fortress Biotech's Restructuring Costs (Quarter) stood at $315000.0 in 2016, then soared by 373.97% to $1.5 million in 2017, then increased by 15.61% to $1.7 million in 2018.
  • Its Restructuring Costs stands at $1.7 million for Q3 2018, versus $2.3 million for Q2 2018 and $1.8 million for Q1 2018.